Cesar Tasilla Ramos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cesar Tasilla Ramos has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Enzo Renatto Bazualdo-Fiorini
Universidad Nacional de Cajamarca
1 shared publication - Heidy Gamboa Mendo
Faculty of Medicine, National University of Cajamarca, Cajamarca, Peru
1 shared publication - Maicol Cortez-Sandoval
Escuela de Medicina Humana, Universidad Científica del Sur, Lima 15067, Peru
1 shared publication - Segundo Bueno Ordoñez
Universidad Nacional de Cajamarca. Perú
1 shared publication - Silvia Zavaleta
Department of Cardiology, Edgardo Rebagliati Martins National Hospital, Lima, Peru
1 shared publication - Yasmin Carhuamaca
Department of Cardiology, Edgardo Rebagliati Martins National Hospital, Lima, Peru
1 shared publication
Latest Publications
- Open Access
- 14 January 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (7) , 106515
Reversible 2:1 Atrioventricular Block After Chronic Coronary Revascularization
- 14 January 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (7) , 106515
Open AccessReversible 2:1 Atrioventricular Block After Chronic Coronary Revascularization
- Open Access
- 1 January 2026
- Published by South American Publishing in Salud Integral y Comunitaria
- Vol. 4, 300
Benefits and limitations of minimally invasive surgery in coronary revascularization: a systematic review
Coronary artery disease is one of the leading causes of mortality in the world, with treatments such as coronary artery bypass surgery seeking to restore arterial flow. Traditionally, this procedure is performed via sternotomy, with significant recovery times and risks. For this reason, minimally invasive surgery (MIDCAB) has emerged as a promising alternative, reducing complications. This work evaluates the benefits and limitations of MIDCAB. METHODS: A search was conducted in SCOPUS, PUBMED and SCIELO for studies published between 2020 and 2025, in Spanish and English, with open access, cohort and retrospective studies that addressed mortality rates, perioperative complications, hospitalization and recovery times. The final synthesis was based on 20 articles after filtering. RESULTS show that MIDCAB has low perioperative mortality rates (0.6%-3.5%) and limited complications, such as stroke (0%-2.3%) and perioperative myocardial infarction (0.6%-1, 6%). Hospitalization and recovery times were also shorter, with average ICU stays of 0.4 to 6.6 days. In the long term, MIDCAB showed a 10-year survival of 94.3%, highlighting its durability and effectiveness. CONCLUSION, MIDCAB represents a safe and effective option for coronary revascularization, especially in patients at high surgical risk or with limitations for more invasive procedures. However, the heterogeneity in the studies and the predominance of retrospective designs underscore the need for more robust prospective investigations to confirm these findings and guide clinical practice.
- 1 January 2026
- Published by South American Publishing in Salud Integral y Comunitaria
- Vol. 4, 300
Open AccessBenefits and limitations of minimally invasive surgery in coronary revascularization: a systematic review
Coronary artery disease is one of the leading causes of mortality in the world, with treatments such as coronary artery bypass surgery seeking to restore arterial flow. Traditionally, this procedure is performed via sternotomy, with significant recovery times and risks. For this reason, minimally invasive surgery (MIDCAB) has emerged as a promising alternative, reducing complications. This work evaluates the benefits and limitations of MIDCAB. METHODS: A search was conducted in SCOPUS, PUBMED and SCIELO for studies published between 2020 and 2025, in Spanish and English, with open access, cohort and retrospective studies that addressed mortality rates, perioperative complications, hospitalization and recovery times. The final synthesis was based on 20 articles after filtering. RESULTS show that MIDCAB has low perioperative mortality rates (0.6%-3.5%) and limited complications, such as stroke (0%-2.3%) and perioperative myocardial infarction (0.6%-1, 6%). Hospitalization and recovery times were also shorter, with average ICU stays of 0.4 to 6.6 days. In the long term, MIDCAB showed a 10-year survival of 94.3%, highlighting its durability and effectiveness. CONCLUSION, MIDCAB represents a safe and effective option for coronary revascularization, especially in patients at high surgical risk or with limitations for more invasive procedures. However, the heterogeneity in the studies and the predominance of retrospective designs underscore the need for more robust prospective investigations to confirm these findings and guide clinical practice.